Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients

  • Ahmed Abdel-Hady Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Ali El-Hindawi Faculty of Medicine Cairo University, Cairo
  • Olfat Hammam Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Heba Khalil Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Sara Diab Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Soulafa Abd El-Aziz Faculty of Medicine Cairo University, Cairo
  • Mohamed Badawy Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Ahmed Ismail Faculty of Medicine Cairo University, Cairo
  • Noha Helmy National Research Center El Doki, Giza
  • Nora Kamel National Research Center El Doki, Giza
  • Shady Anis Faculty of Medicine Cairo University, Cairo
  • Amr El Kholy Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Khalid Al Osili Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Afaf Abdel-Hady Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Hani Nour Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Maha Akl Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
Keywords: Prostatic carcinoma, ERG Immunoexpression, TMRPSS2-ERG, Fluorescence in situ hybridization (FISH), High grade prostatic intraepithelial neoplasia

Abstract

AIM: Prostate cancer (PCa) is the second most common cancers in men worldwide. Its incidence can be influenced by several risk factors including genetic susceptibility. Therefore the search for the expression of a certain gene (ERG) and its rearrangement could give us clues for proper identification of PCa. And the study of ERG expression and its comparison to FISH in Egyptian patients can show whether ERG immunophenotype could be used instead of FISH, as it is cheaper.

MATERIALS AND METHODS: This study was performed on 85 cases of PCa, showing 30 cases with HGPIN and 30 cases of prostatic hyperplasia. All were immunohistochemistry stained using ERG monoclonal rabbit antihuman antibody was used (clone: EP111). FISH analysis was performed in 38 biopsies of PCa cases to detect TMRPSS2-ERG rearrangement using the FISH ZytoLight TriCheck Probe (SPEC TMRPSS2-ERG).

RESULTS: ERG expression was found in 26% of PCa cases and 20% of HGPIN cases. FISH analysis showed fusion of 21 cases of PCa (out of 22 cases showing ERG immunoexpression).

CONCLUSION: Our findings emphasise that only malignant and pre-malignant cells and not benign cells from the prostate stain positive. ERG expression may offer a simpler, accurate and less costly alternative for evaluation of ERG fusion status in PCa.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Ferlay J, Soerjomataram, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns. In: GLOBOCAN 2012. Int J Cancer. 2015;136: E359–E386.

Epstein JI, Algaba F, Allsbrook, WC, Bastacky S, Boccon-Glbod L, De Marzo A, et al. Acinar adenocarcinoma. In: Eble JN, World Health Organization, International Agency for Research on Cancer, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organ. Lyon: IARC Pres, 2004: 162–192.

Donovan MJ, Cordon-Cardo C. Predicting high-risk disease using tissue biomarkers. Curr Opin Urol. 2013; 23(3): 245–5. https://doi.org/10.1097/mou.0b013e32835f89cc

Ghei, M, Pericleous S, Kumar A, Miller R, Nathan, Maraj B, et al. Finger-guided transrectal biopsy of the prostate: a modified, safer technique. Ann R Coll Surg Engl. 2005; 87 (5): 386–7. PMid:16402467 PMCid:PMC1963966

Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PHH, Han M, et al. Prostate specific antigen best practice statement. J Urol. 2009;182: 2232-2241. https://doi.org/10.1016/j.juro.2009.07.093 PMid:19781717

Ayala AG, Ro JY. Prostatic intraepithelial neoplasia: recent advances. Arch Pathol Lab Med. 2007;131: 1257–6. PMid:17683188

Epstein JI. Precursor lesions to prostatic adenocarcinoma. Virchows Arch. 2009; 454: 1–16. https://doi.org/10.1007/s00428-008-0707-5 PMid:19048290

Isabelle M, Hillel K, David B. Atypical Small Acinar Proliferation in the Prostate. AJSP. 2008;13 (4): 129-134.

Helin H, Lundin M, Laakso M, Lundin J, Helin J, Isola J. Virtual Microscopy in Prostate Histopathology: Simultaneous Viewing of Biopsies Stained Sequentially With Hematoxylin and Eosin, and α-Methylacyl-Coenzyme A Racemase/p63 Immunohistochemistry. Journal of Urology. 2006;175 (2): 495-499. https://doi.org/10.1016/S0022-5347(05)00164-3

Kitagawa Y, Mizokami A, Namiki M. Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening. Prostate Int. 2013;1:65–68. https://doi.org/10.12954/PI.12017 PMid:24223404 PMCid:PMC3814114

Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L et al. Serum concentrations of prostate specific antigen and its complex with a-1-antichymotrypsin before diagnosis of prostatic cancer. Lancet. 1994;344:1594–1598. https://doi.org/10.1016/S0140-6736(94)90405-7

Ceylan C, Gazel E, Keleş İ, Doluoğlu Ö, Yığman M. Can the Free/Total PSA Ratio Predict the Gleason Score Before Prostate Biopsy? Curr Urol. 2016;9(1):24-7. https://doi.org/10.1159/000442846 PMid:26989367 PMCid:PMC4789969

Vanaja DK, Cheville JC, Iturria SJ, Young CY. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003;63(14):3877–3882. PMid:12873976

Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clin Cancer Res. 2009;15(14):4706-11. https://doi.org/10.1158/1078-0432.CCR-08-2927 PMid:19584163 PMCid:PMC3717524

Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol. 2009;56(2):275–286. https://doi.org/10.1016/j.eururo.2009.04.036 PMid:19409690

Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8(7):497–511. https://doi.org/10.1038/nrc2402 PMid:18563191 PMCid:PMC2711688

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310: 644–648. https://doi.org/10.1126/science.1117679 PMid:16254181

Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res. 2008;14 (11):3380-5. https://doi.org/10.1158/1078-0432.CCR-07-5194 PMid:18519767 PMCid:PMC3717517

Chen S, Deniz K, Sung YS, Zhang L, Dry S, Antonescu CR: Ewing sarcoma with ERG gene rearrangements: A molecular study focusing on the prevalence of FUS-ERG and common pitfalls in detecting EWSR1-ERG fusions by FISH. Genes Chromosomes Cancer. 2016;55(4):340-9. https://doi.org/10.1002/gcc.22336 PMid:26690869 PMCid:PMC5006947

Gavrilov D, Kenzior O, Evans M, Calaluce R, Folk WR. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur J Cancer. 2001;37(8):1033–1040. https://doi.org/10.1016/S0959-8049(01)00077-6

Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2016;69(3):428-35. https://doi.org/10.1016/j.eururo.2015.06.046 PMid:26166626 PMCid:PMC5002992

Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. Am J Surg Pathol. 2011;35:1014-1020. https://doi.org/10.1097/PAS.0b013e31821e8761 PMid:21677539 PMCid:PMC3505676

Berg KD, Brasso K, Thomsen FB, Roder MA, Holten-Rossing H, Toft BG, et al. J Clin Pathol. 2015;0: 1-7.

Hilal L, Shahait M, Mukherji D. Charafeddine M, Farhat Z, Temraz S, et al. Prostate cancer in the Arab world: A view from the inside Clin Genitourin Cancer. 2015;13(6):505-11. https://doi.org/10.1016/j.clgc.2015.05.010 PMid:26149392

Gronberg H. Prostate cancer epidemiology. Lancet. 2003;361: 859–864. https://doi.org/10.1016/S0140-6736(03)12713-4

Cuzick J, Thorat MA, Andriole G, Brawley O, Brown P, Culig Z, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15:e484-e492. https://doi.org/10.1016/S1470-2045(14)70211-6

Rubio-Briones J, Fernandez-Serra A, Calatrava A, García-Casado Z, Rubio L, Bonillo MA, et al. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. J Urol. 2010;183(5):2054-61. https://doi.org/10.1016/j.juro.2009.12.096 PMid:20303538

Hoogland AM, Jenster G, van Weerden WM, Trapman J, Kwast Tvd, Roobol MJ, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Mod Pathol. 2012;25(3):471–479. https://doi.org/10.1038/modpathol.2011.176 PMid:22080055

Schaefer G, Mosquera J-M, Ramoner R, Park K, Romianel A, Steiner E, et al. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer and Prostatic Disease. 2013;16: 132–138. https://doi.org/10.1038/pcan.2013.4

Tomlins SA, Palanisamy N, Siddiqi J, Chinnaiyan AM, Kunju LP. Antibody-Based Detection of ERG Rearrangements in Prostate Core Biopsies, Including Diagnostically Challenging Cases. ERG Staining in Prostate Core Biopsies. Arch Pathol Lab Med. 2012;136:935–946. https://doi.org/10.5858/arpa.2011-0424-OA PMid:22849743 PMCid:PMC3667408

Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7(4):233–45. https://doi.org/10.1038/nrc2091 PMid:17361217

Furusato B, van Leenders GJ, Trapman J, Kimura T, Egawa S, Furusato M, et al. Immunohistochemical ets-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathol Int. 2011;61(7):409–14. https://doi.org/10.1111/j.1440-1827.2011.02675.x PMid:21707844

Lee K, Chae JY, Kwak C, Ku JH, Moon KJ. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. Urology. 2010;76(5):1268.e7-13. https://doi.org/10.1016/j.urology.2010.06.010 PMid:20800881

Miyagi Y, Sasaki T, Fujinami K et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol. 2010;23(11):1492-8. https://doi.org/10.1038/modpathol.2010.149 PMid:20693979

Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C, et al. ETS rearrangements and prostate cancer initiation. Nature. 2009;457(7231):E1; discussion E2-3.

Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol. 2009 ;22(8):1083-93. https://doi.org/10.1038/modpathol.2009.69 PMid:19407851 PMCid:PMC2760294

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression. Cancer cells. 2010;17(5): 443-454. https://doi.org/10.1016/j.ccr.2010.03.018 PMid:20478527 PMCid:PMC2874722

Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol. 2011;24(8): 1120-7. https://doi.org/10.1038/modpathol.2011.56 PMid:21499238 PMCid:PMC3441178

Zhang S, Pavlovitz B, Tull J, Wang Y, Deng FM, Fuller C. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization. Diagn Mol Pathol. 2010;19(3):151-6. https://doi.org/10.1097/PDM.0b013e3181bb216a PMid:20736744

Dai MJ, Chen LL, Zheng YB, Chen W, Tao ZH, Weng ZL, et al. Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer. Zhonghua Yi Xue Za Zhi. 2008;88(10):669-73. PMid:18642766

Mehra R, Han B, Tomlins SA, Wang L, Menon A, Wasco MJ, et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007;67(17):7991-5. https://doi.org/10.1158/0008-5472.CAN-07-2043 PMid:17804708

Gopalan A, Leversha M A, Dudas M E, Maschino A C, Chang J, et al. TMPRSS2–ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry. Histopathology 2013;63, 279–286. https://doi.org/10.1111/his.12153 PMid:23701505 PMCid:PMC3723763

Fine SW, Gopalan A, Leversha MA, Al-Ahmadie HA, Tickoo SK, Zhou Q, et al. TMPRSS2-ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features. Mod Pathol. 2010;23(10):1325-33. https://doi.org/10.1038/modpathol.2010.120 PMid:20562851 PMCid:PMC3413944

Bismar TA, Dolph M, Teng L-H, Liu S, Donnelly B. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. Eur J Cancer. 2012;48(4):538–546. https://doi.org/10.1016/j.ejca.2012.01.001 PMid:22300588

Hagglof C, Hammarsten P, Str€omvall K, Egevad L, Josefsson A, Stattin P, Granfors T, et al. TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS ONE. 2014;9(2):e86824. https://doi.org/10.1371/journal.pone.0086824 PMid:24505269 PMCid:PMC3914792

Qi M, Yang X, Zhang F, Lin T, Sun X, et al. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients. PLoS One. 2014;9(2):e84959. https://doi.org/10.1371/journal.pone.0084959 PMid:24516518 PMCid:PMC3917829

de Muga S, Herandez S, Salido M, Lorenzo M, Agell A, Juanpere-Rodero, et al. CXCR4 mRNA overexpression in high grade prostate tumors: Lack of association with TMPRSS2-ERG rearrangement. Cancer Biomark. 2012;12(1):21–30. https://doi.org/10.3233/CBM-2012-00288 PMid:23321466

Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res. 2007;67(18):8504-10. https://doi.org/10.1158/0008-5472.CAN-07-0673 PMid:17875689

FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-coll A, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer. 2008;11;8:230.

Saramaki O, Harjula A, Martikainen P, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res. 2008;14(11):3395-400. https://doi.org/10.1158/1078-0432.CCR-07-2051 PMid:18519769

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera JM, Setlur S, et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006 ;66(17):8337–8341. https://doi.org/10.1158/0008-5472.CAN-06-1482 PMid:16951139

Rouzier C, Haudebourg J, Carpentier X, Valério L, Amiel J, Michiels JF, et al. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. Cancer Genet Cytogenet. 2008;183(1):21-7. https://doi.org/10.1016/j.cancergencyto.2008.01.021 PMid:18474293

Lee SL, Yu D, Wang C, Saba R, Liu S, Trpkov K, et al. ERG Expression in Prostate Needle Biopsy: Potential Diagnostic and Prognostic Implications. Appl Immunohistochem Mol Morphol. 2015;23(7):499-505. https://doi.org/10.1097/PAI.0000000000000119 PMid:25517865

Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Lorente JA, Fumado L et al. Association of erg and tmprss2-erg with grade, stage, and prognosis of prostate cancer is dependent on their expression levels. Prostate. 2015;75(11):1216–26. https://doi.org/10.1002/pros.23004 PMid:25939480

Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596–4599. https://doi.org/10.1038/sj.onc.1210237 PMid:17237811

Jiang H, Mao X, Huang X, Zhao J, Wang L, Xu J, Zhang H, Lu Y, Yu Y. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer. Tumour Biol. 2016;37(9):12397-12402. Erratum in: Tumour Biol. 2016;37(10):14331. https://doi.org/10.1007/s13277-016-5116-9 PMid:27320318

Svensson MA, Perner S, Ohlson AL, et al. A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort. Appl Immunohistochem Mol Morphol. 2014;22:136–41. https://doi.org/10.1097/PDM.0b013e31829e0484 PMid:24517914

Braun M, Goltz D, Shaikhibrahim Z, Vogel W, Scheble V, Sotlar K, et al. ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer—a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis. 2012;15:165–9. https://doi.org/10.1038/pcan.2011.67 PMid:22231490

Published
2017-03-20
How to Cite
1.
Abdel-Hady A, El-Hindawi A, Hammam O, Khalil H, Diab S, Abd El-Aziz S, Badawy M, Ismail A, Helmy N, Kamel N, Anis S, El Kholy A, Al Osili K, Abdel-Hady A, Nour H, Akl M. Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients. Open Access Maced J Med Sci [Internet]. 2017Mar.20 [cited 2020Oct.26];5(2):147-54. Available from: https://www.id-press.eu/mjms/article/view/oamjms.2017.037
Section
A - Basic Science

Most read articles by the same author(s)